High Risk DLBCL in Younger Patients: Should ASCT be Declined in the Era Pos-Rituximab?

Introdution Optimal treatment of young patients with high-risk diffuse large B-cell lymphoma (DLBCL) remains a matter of debate. With the addition of rituximab, response rates (RR) and overall survival (OS) have improved significantly, but the best treatment option for this subset of patients with h...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2019-11, Vol.134 (Supplement_1), p.5356-5356
Main Authors: Quintela, Miguel, Vieira, Iolanda, Moreira, Cláudia, Chacim, Sérgio, Domingues, Nelson, Oliveira, Isabel, Espirito Santo, Ana, Moreira, Maria Ilidia, Martins, Ângelo, Viterbo, Maria Luisa, Pereira, Dulcineia, Mariz, Jose Mario
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introdution Optimal treatment of young patients with high-risk diffuse large B-cell lymphoma (DLBCL) remains a matter of debate. With the addition of rituximab, response rates (RR) and overall survival (OS) have improved significantly, but the best treatment option for this subset of patients with high risk DLBCL is not consensual. Historically, these patients are treated with conventional immunochemotherapy protocols (RCHOP - Rituximab + cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by autologous stem cell transplantation (ASCT) as a consolidation treatment. Several studies tried to clear the exact role of ASCT, and others were design to answer about addition of other drugs to RCHOP, without conclusive results. Recently, our department review the protocol according to the state of the art, and an intensification of treatment was made for high risk DLBCL in young patients (
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2019-131254